# Ultragenyx Pharmaceutical Inc. (RARE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.30, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Ultragenyx Pharmaceutical Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 10.37**. A PEG of 10.37 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 2.1×**. Each dollar of revenue is priced at 2.1×.
- **Free-cash-flow yield: -32.4%** (5-yr avg -13.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -73.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -85.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: 718.8%**. A 718.8% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on assets: -38.3%**. Each dollar of assets produces -38.3% of profit.

## Growth
- **Revenue growth (1 yr): 20.2%** (3-yr 22.8%/yr, 5-yr 19.9%/yr). Revenue grew 20.2% over the last year, against 19.9% a year compounded over five years.
- **EPS growth (1 yr): 7.3%**. Earnings per share rose 7.3%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 2.48** (quick 2.48). Current assets cover the next year's liabilities 2.48 times.
- **Altman Z-score: 0.22**. A Z-score of 0.22 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (19 analysts). 19 analysts cover Ultragenyx Pharmaceutical Inc.; the consensus is buy, with an average price target of $27.00 (+76% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -51.1%** (YTD -33.5%, 3-mo -30.2%). The shares are down 51.1% over twelve months including dividends.
- **From 52-week high: -61.6%** (10.8% above the low). Trading 62% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 21**. An RSI of 21 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.13** (volatility 80%). Beta of 1.13 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RARE · Page: https://foliofundamentals.com/stocks/rare

Not investment advice.